Why Are Alkermes Shares Trading Higher Today?

Loading...
Loading...

Alkermes plc's ALKS Q4 sales increased 16% Y/Y to $324.5 million, beating the consensus of $308.69 million.

  • Net sales of proprietary products were $178.9 million, compared to $148.96 million in the prior year.
  • Net sales of Vivitrol were $92.04 million, compared to $80.05 million in the prior year. Net sales of Aristada were $78.67 million, compared to $68.91 million.
  • Manufacturing and royalty revenues were $143.37 million, compared to $130.89 million in the prior year.
  • Royalty revenues from the long-acting INVEGA products were $81.14 million, compared to $76.52 million in the prior year.
  • The Company reported an adjusted EPS of $0.23, compared to $0.10, beating the consensus of $0.11.
  • Related: Alkermes Schizophrenia Med Shows Lower Mean Weight Gain In Early Illness With Schizophrenia.
  • Guidance: Alkermes expects FY22 sales of $1 billion - $1.09 billion, below the consensus of $1.15 billion.
  • The outlook expects Vivitrol sales of $355 million – $385 million, Aristada revenues of $290 million – $320 million, and Lybalvi sales of $55 million – $75 million.
  • For FY22, the Company expects adjusted EPS of ($0.18) – $0.00, compared to the Wall Street estimate of $0.35.
  • Price Action: ALKS shares are trading 13.30% higher at $26.40 on the last check Wednesday.
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...